Professor Iain McInnes
Director of Institute of Infection, Immunity and Inflammation
‘At Glasgow, we are committed to improving the quality of lives for people with a range of chronic diseases. In particular, we are developing ‘precision medicine’ based strategies for those people suffering from arthritis to improve their quality of life.’
One of the leading figures in global research into rheumatoid and psoriatic arthritis, Professor McInnes has been widely published - his work has been hugely influential in driving new approaches and treatments for inflammatory diseases.
Iain is Director of the Institute of Infection, Immunity and Inflammation at the University of Glasgow. He is an authority on the pathogenesis and treatment of inflammatory arthritis. His early studies identified the expression and functional importance of a number of cytokines in rheumatoid synovitis and have extended since to explore the pathways that drive inflammation in the skin and joints of people with psoriatic arthritis. Latterly he has developed a substantial programme investigating the mechanisms and treatment of common co-morbidities e.g. heart disease and lipid disorders, that afflict people with arthritis.
Professor McInnes has built an internationally recognised research programme that aims to understand the cellular and molecular pathways behind the development of inflammatory joint diseases. In particular, his research advances have provided a platform for major pharmaceutical companies to develop pre-clinical findings into clinical trials of innovative therapies.
Professor Iain McInnes was awarded the Sir James Black Prize Medal by the Royal Society of Edinburgh for his “outstanding contribution to the field of immunology”.
Professor McInnes has a major interest in the pathogenesis of rheumatoid arthritis, psoriatic arthritis and their related co-morbidities. He leads a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics therafter.